CATB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 rugs. 2021 @ 07:00):

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States...

Stats
Dzisiejszy wolumen	98 872.00
Średni wolumen	528 916
Kapitalizacja rynkowa	234.86M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.105 (1.23%)

Insider Trading

Date	Person	Action	Amount	type
2021-06-08	Harshbarger Benjamin	Buy	200 000	Stock Option (right to buy)
2021-06-02	Callori Fred	Buy	85 000	Stock Option (right to buy)
2021-06-02	Violin Jonathan	Buy	85 000	Stock Option (right to buy)
2021-06-02	Clauser Noah	Buy	600 000	Stock Option (right to buy)
2021-06-02	Kishbauch Michael D	Buy	100 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 86 transactions
Buy: 7 288 895 \| Sell: 328 827

Wolumen Korelacja

Długi: -0.05 (neutral)

Krótki: 0.18 (neutral)

Signal:(67.933) Neutral

Catabasis Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
MESO	0.957
SCTL	0.931
VFF	0.926
MOTNU	0.919
SGRP	0.916
SMTC	0.916
LABP	0.912
VNET	0.911
STOK	0.911
TTOO	0.908

10 Najbardziej negatywne korelacje
ATHN	-0.971
PTRA	-0.964
ARIZ	-0.95
GBRG	-0.91
PAE	-0.908
SCR	-0.902
ARVL	-0.9
EBSB	-0.898
TYHT	-0.894
AMRS	-0.893

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Catabasis Pharmaceuticals Korelacja - Waluta/Towar

-0.08
( neutral )

0.32
( neutral )

-0.21
( neutral )

-0.17
( neutral )

-0.29
( neutral )

-0.45
( neutral )

Financial Reports:

No articles found.

Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.